Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 1, 2013, Pages 14-22

  Rashikh, Azhar ^a   Pillai, Krishna K ^a   Ahmad, Shibli J ^a   Akhtar, Mohammad ^a   Najmi, Abul K ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

anthracycline; Direct renin inhibitor; nephrotoxicity; podocyte; renin angiotensin system

Indexed keywords

ALBUMIN; ALISKIREN; CATALASE; CREATININE; DOXORUBICIN; GLUTATHIONE; MALONALDEHYDE; PROTEIN; RENIN; SUPEROXIDE DISMUTASE; UREA;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULUS BASEMENT MEMBRANE; KIDNEY PARENCHYMA; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PODOCYTE; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; UREA BLOOD LEVEL;

AMIDES; ANIMALS; ANTIOXIDANTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BODY WEIGHT; CREATININE; DOXORUBICIN; FUMARATES; KIDNEY DISEASES; LIPID PEROXIDATION; ORGAN SIZE; OXIDATIVE STRESS; PODOCYTES; RATS; RATS, WISTAR; RENIN; SERUM ALBUMIN; SYSTOLE; UREA;

EID: 84874057493     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312459980     Document Type: Article

References (42)

1. Blum RH, Carter SK. Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med. 1974 ; 180: 249-259
2. Jovanovic D, Dimitrijevic J, Varagic J, et al. Effects of captopril on morphologic changes in kidney of spontaneously hypertensive rats with adriamycin nephropathy. Renal Fail. 1998 ; 20: 451-458
3. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998 ; 339: 900-905
4. Bertani T, Poggi A, Pozzoni R, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest. 1982 ; 46: 16-23
5. Milner LS, Wei SH, Houser MT. Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea. J Lab Clin Med. 1991 ; 118: 427-434
6. Zima T, Tesar V, Stipek S, et al. The influence of cyclosporin on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Nephron. 1997 ; 75: 464-8
7. Liu LL, Li QX, Xia L, et al. Differential effects of dihydropyridine calcium antagonists on doxorubicin induced nephrotoxicity in rats. Toxicology. 2007 ; 231: 81-90
8. El-Shitany NA, El-Haggar S, El-Desoky K. Silymarin prevents adriamycin-induced cardiomyopathy and nephropathy in rats. Food Chem Toxicol. 2008 ; 46: 2422-2428
9. Ibrahim MA, Ashour OM, Ibrahim YF, et al. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiomyopathy and nephropathy. Pharmacol Res. 2009 ; 60: 373-381
10. Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?. Arch Intern Med. 2000 ; 160: 1905-1911
11. Kaplan NM. Angiotensin II-receptor blockers: will they replace angiotensin converting enzyme inhibitors in the treatment of hypertension?. J Hum Hypertens. 2000 ; 14: S87 - S90
12. Scholey JW, Miller PL, Rennke HG, et al. Effect of converting enzyme inhibition on the course of Adriamycin induced nephropathy. Kidney Int. 1989 ; 36: 816-822
13. Squadrito F, Macchiorelli G, Santoro G, et al. Effects of captopril on the development of rat doxorubicin nephropathy. Histol Histopathol. 1992 ; 7: 223-222
14. Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ inducing property. Med Hypoth. 2005 ; 64: 476-478
15. Mansouru M, El-kashef H, Al-shabanah O. Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats. Pharmacol Res. 1999 ; 39: 239-45. :
16. Smithies O. A mouse view of hypertension. Hypertension. 1997 ; 30: 1318-1324
17. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998 ; 32: 387-392
18. Gradman AH, Schmieder RE, Robert L, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 ; 111: 1012-1018
19. Rashikh A, Najmi AK, Akhtar M, et al. Protective effects of Aliskiren in doxorubicin induced acute cardiomyopathy in rats. Hum Exp Toxicol. 2011 ; 30: 102-109
20. Porstmann T, Kiessig ST. Enzyme immunoassay techniques, an overview. J Immunological Methods. 1992 ; 150: 5-21
21. Young DS. Effects of drugs on clinical laboratory tests. Ann Clin Biochem. 1997 ; 34: 579-81
22. Koller A. Proteins. In: Clinical chemistry: theory, analysis and correlation. (eds) Toronto: CV Mosby, 1984, pp.1268-1327.
23. Wang JJ. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy evidence for antifibrogenic activities. Diabetes. 2006 ; 55: 1678-1685
24. Fawcett JK, Scott JE. A rapid and precise method for the determination of urea. J Clin Pathol. 1960 ; 13: 156-159
25. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979 ; 95: 359-364
26. Sedlack J, Lindsay RH. Estimation of total protein bound and non-protein bound sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968 ; 25: 192-205
27. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974 ; 47: 469-474
28. Clairborne A. Catalase activity. In: Greenwald RA (ed.). Handbook of methods of oxygen free radical research. CRC Press, Boca Raton, Florida: 1985, pp.283-284.
29. Lowry OH, Rosebrough NH, Farr AL, et al. Protein measurements with the Folin Phenol Reagent. J Biol Chem. 1951 ; 193: 265-275
30. Pogodina LS, Shornikova MV, Chentsov IS. Electron microscopy description of cardiomyocytes from the left ventricle of rat heart after apoptosis induction by isoproterenol. Izvestiia Akademii nauk. Seriia biologicheskaia / RossiÄskaia akademiia nauk. 2006 ; 1: 26-37
31. Mifsud SA, Allen TJ, Bertram JF, et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia. 2001 ; 44: 878-882
32. White KE, Bilous RW. Estimation of podocyte number: a comparison of methods. Kidney Int. 2004 ; 66: 663-667
33. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int. 2007 ; 71: 1205-1214
34. Bertani T, Poggi A, Pozzoni R. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest. 1982 ; 46: 16-23
35. O'Donnell MP, Michels L, Kasiske B, et al. Adriamycin induced chronic proteinuria: a structural and functional study. J Lab Clin Med. 1985 ; 106: 62-67
36. Okuda S, Oh Y, Tsuruda H, et al. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int. 1986 ; 29: 502-510
37. Morales-Olivas Francisco J, Estan L. Plasma renin activity. Role of the direct renin inhibition. Rev Esp Cardiol. 2011 ; 11: 3-7
38. Otaki Y, Miyauchi N, Higa M, et al. Dissociation of NEPH1 from nephrin is involved in development of a rat model of focal segmental glomerulosclerosis. Am J Physiol Renal Physiol. 2008 ; 295: F1376 - F1387
39. Zhu W, Zou Y, Aikawa R, et al. MAPK superfamily plays an important role in daunomycin induced apoptosis of cardiac myocytes. Circulation. 1999 ; 100: 2100-2107
40. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. British J Pharmacol. 2000 ; 129: 231-234
41. Yilmaz S, Atessahin A, Sahna E, et al. Protective effect of lycopene on adriamycin-induced cardiomyopathy and nephropathy. Toxicol. 2006 ; 218: 164-171
42. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003 ; 83: 253-307